LASOR: Switching to Nilotinib in CML-CP with Suboptimal Response to Imatinib


LASOR: Switching to Nilotinib in CML-CP with Suboptimal Response to Imatinib
Slides from a presentation at ASH 2013 and transcribed comments from recent interviews with Jorge E Cortes, MD (1/24/14) and Hagop M Kantarjian, MD (1/29/14)
Cortes JE et al. Switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with suboptimal cytogenetic response (CyR) on imatinib: First results of the LASOR trial. Proc ASH 2013;Abstract 95.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.